Initial treatment to delay the onset of type 1 diabetes in certain age groups, approved from Food and Drug Administration (FDA) USA. drug on which it is based teplizumab called Tzieldand produced by the pharmaceutical company Provention Biography.
“Today’s approval of world-class therapy adds significant new treatment option for some at-risk patients”says John Sharretts, Diabetes, Lipid Disorders and Obesity Division FDA’s “Potential of drug to delay clinical diagnosis of type 1 diabetes can provide patients months or years without the burden of disease”.
Type 1 diabetes (T1D) occurs when a person’s immune system attacks the cells that produce insulin, the hormone that makes it up. regulates blood sugar levels. The disease progresses over time; Stage 1 represents the first sign of the disease. The second stage involves autoimmunity of beta cells, resulting in an imbalance in blood sugar levels. The third and final condition manifests itself as follows: symptomatic and irreversible disease to all effects.
You will be surprised to know that T1D was first diagnosed in children and teenagers. In this case, what is expected from patients insulin injections for the rest of their lives. The goal is to always keep blood sugar under control.
“The progression of T1D can be particularly challenging; In patients transitioning from stage 2 to stage 3 of T1D develop diabetic ketoacidosispossibly life threatening. 50% of stage 3 patients have this condition”, said Dr. Eleanor Ramos Chief Medical Officer from Provention Biography.
In clinical studies, Tzield It has been proven to have the right properties for delay the progression of diabetes type 1 to phase 2 to phase 3, as previously mentioned, predicting the onset of symptomatic disease. Recipients of the humanized antibody teplizumab announced a delay of over two years.
Source: Every Eye